ZNTL · Zentalis Pharmaceuticals, Inc.
$2.79
+0.27 (+10.52%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$184.91M
Shares
71.67M
Volume · Oct 5
2.72M
Avg daily vol (3M)
1.18M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.52
Open$2.64
Day$2.50–2.65
52W close$1.28–6.61
Avg vol 30d1.1M
Short int4.8M · 6.7% float · 5.2d
Short vol61%
Last earningsFeb 27, 2024
DataApr 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$139.54M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-69.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$24.78M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
+51.8%
Trailing year
Short interest
6.7%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−33%
below
RSI (14)
26
oversold
MACD trend
Negative
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−55%
trailing
YTD return
+87%
this year
Relative strength
−67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +33 funds added
Insider flow
Accumulating
Net +$15.2M over 90 days · 0% sells
Short interest
Falling
6.68% of float · ▼ -4.1% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
114 holders — mid 3-yr range
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-125.2M
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
26
Neutral
MACD trend
Negative
Bearish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +33 funds added
Insider flow
Accumulating
Net +$15.2M over 90 days · 0% sells
Short interest
Falling
6.68% of float · ▼ -4.1% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
114 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $3 · 23%
Range high $7
vs 200-day avg -26%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $175M | as of 6/30/26 | — |
| Complete response rate (Azenosertib + EV in preclinical TNBC model) | 87.5% | AACR 2026 | — |
| Median duration of response (Cyclin E1+) | 6.3 | DENALI Part 1b | — |
| Median progression free survival (Cyclin E1+) | 4.1 | DENALI Part 1b | — |
| Ongoing responders (Cyclin E1+) | 4 | DENALI Part 1b | — |
| ORR in response-evaluable patients (Cyclin E1 IHC+) | 34.9% | DENALI Part 1b | — |
| ORR, ITT (All treated patients) | 18.6% | DENALI Part 1b | — |
| ORR, ITT (Cyclin E1 IHC+) | 31.3% | DENALI Part 1b | — |
| Serious TRAEs | -21.6% | DENALI Part 1b | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZNTL
this stock
Zentalis Pharmaceuticals, Inc.
|
$184.91M | +86.7% | -100.0% | — | 6.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZNTL | -6.7% | -38.7% | -54.7% | -9.0% | +86.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -6.5% | -38.2% | -66.9% | -10.0% | +73.8% |